Advent Therapeutics Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $225K
Latest Deal Amount
  • Investors
  • 2

Advent Therapeutics General Information

Description

Developer of therapies designed for micro-orphan applications. The company develops a prenatal, neonatal and pediatric drug for orphans to cure disorder in newborn infants in the intensive care unit (ICU), enabling pediatricians and healthcare professionals to care for the fragile in an advanced manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 6500 Old Carversville Road
  • Lumberville, PA 18933
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Advent Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 01-Jan-2018 $225K 00000 Completed Product Development
3. Early Stage VC 12-Sep-2016 00000 00000 Completed Product Development
2. Seed Round 19-Aug-2015 $120K $120K Completed Product Development
1. Seed Round 11-Dec-2014 Completed Product Development
To view Advent Therapeutics’s complete valuation and funding history, request access »

Advent Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Thomas Hofmann Ph.D Chief Scientific Advisor
David Lopez JD Co-Founder, Chief Financial Officer, Chief Business Officer & President
To view Advent Therapeutics’s complete executive team members history, request access »

Advent Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
U.S. Department of Health and Human Services Government 000 0000 000000 0
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
To view Advent Therapeutics’s complete investors history, request access »